With the FLExDUX4 mice already available from Jackson Labs, this initial analysis provides the platform for allowing the field to move forward with investigations of FSHD pathogenic mechanisms, and testing the efficacy of numerous potential therapeutic approaches targeting DUX4-fl mRNA and protein. Here, FLT3LG is linked to facioscapulohumeral muscular dystrophy.